It’s Time to Sell This Superbug Slayer
Antibiotics were a long-ignored corner of the pharmaceutical world, but they've become red-hot again. A year ago, I told you to buy the biggest of the few antibiotics pure plays on the market. That's paid off. On Monday, Merck announced it would buy the company at $102 per share. That's a 65% gain from when we recommended buying the antibiotics specialist.
You Must Be A Subscriber To View This Content.
If you are already a subscriber, click the login button below to get access. Not yet a subscriber? Checkout our publication below and get access today!
Technology Profits Confidential
With new technologies in mobile computing, biotechnology and 3-D printing, it’s nearly impossible to keep up with the throngs of new innovation and still be able to forecast which companies are set to profit. Technology Profits Confidential is your one-stop shop for the companies of tomorrow’s technology… and how you can profit from them.